drugset / Trial / NCT00305383

Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C

NCT00305383

Phase 2 Terminated 100 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to examine the rapid virologic response (RVR) at combination therapy (CT) Week 4 between groups receiving a standard combination peginterferon alfa-2b/viramidine dosing regimen versus a cohort that receives 4 weeks of viramidine monotherapy prior to the start of peginterferon alfa-2b/viramidine combination therapy.

Timeline

Start
2005-11
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon alfa-2b Protein / enzyme biologic
Subject Taribavirin Small molecule